Oxurion moves forward with the planned acquisition of Axiodis

12 Jun 2025 08:30 CEST

Leuven, BELGIUM – June 12, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the lifting of the condition precedent relating to the completion of the employee information process as per Article L.23-10-1 of the French Commercial Code. This milestone represents a key step towards the final completion of the acquisition of 72% of the share capital of Axiodis CRO by its French subsidiary.

While awaiting the regulatory approval relating to the control of foreign direct investments in France (FDI), which is expected in the coming weeks, Oxurion is now focusing its efforts on finalizing the transaction.

At the same time, the group is accelerating discussions with other strategic targets, particularly in the Toulouse region, with the aim of creating technological and operational synergies with Axiodis. This initiative is part of Oxurion's ambition to build an integrated hub around clinical data, serving clients in the life sciences sector.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments.

The Group's headquarters are located in Leuven, Belgium.

More information: www.oxurion.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

92203_BE0974487192.pdf